For instance, the identification of HER2 amplified or estrogen receptor-positive breast cancer anticipates favorable response to HER2-targeted therapy or hormone therapy [2], EGFR mutation in lung cancer predicts response to EGFR-targeted therapeutic compounds [3], while imatinib in Philadelphia chromosome-positive leukemia predicts a favorable outcome in that context [4]. Here, ERBB2 is linked to lung cancer.